Glooko vs Noom
Side-by-side comparison of AI visibility scores, market position, and capabilities
Glooko is a digital health platform for diabetes and chronic condition management; syncs data from 250+ glucose meters, CGMs, insulin pumps, and wearables; supports remote patient monitoring for clinicians and health systems; raised $100M+;
About
Glooko is a digital health company founded in 2010 and headquartered in Palo Alto, California, that provides a comprehensive platform for diabetes and chronic condition management. The company's technology aggregates data from over 250 connected diabetes devices — including continuous glucose monitors (CGMs), blood glucose meters, insulin pumps, pens, and health wearables — into a single unified platform that serves both patients and their care teams. For patients, Glooko provides a mobile app offering personalized insights, trend analysis, and education based on their glucose, insulin, activity, and nutrition data. For healthcare providers and clinical teams, Glooko's Population Health platform enables remote patient monitoring — allowing endocrinologists, diabetes educators, and primary care physicians to track patient cohorts, identify high-risk individuals, and deliver data-driven care interventions at scale.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.